Anna Martling, MD, PhD, on the ALASCCA Trial in Colorectal Cancer
The randomized, double-blind, multicenter, placebo-controlled ALASCCA Trial screened 3,508 patients across 33 hospitals in Sweden, Denmark, Finland, and Norway for eligibility. They either had stage II or III colon cancer or stage I, II, or III rectal cancer. Ultimately, 626 patients continued on with the trial, including 419 with colon cancer, and 207 with rectal cancer. Anna Martling, MD, PhD, of Karolinska Institutet, and colleagues evaluated the impact of low-dose aspirin on recurrence in this
